University of Wisconsin
School of Medicine and Public Health


Click here for a PubMed search of Mark Burkard's publications.

Denu RA, Sass MM, Johnson JM, Potts GK, Choudhary A, Coon JJ, Burkard ME. 2019. Polo-like kinase 4 maintains centriolar satellite integrity by phosphorylation of centrosomal protein 131 (cep131). J Biol Chem. PMID: 30804208

Jin N, Burkard ME. 2018. Macrod2, an original cause of cin? Cancer Discov. 8(8):921-923. PMID: 30076143

Denu RA, Shabbir M, Nihal M, Singh CK, Longley BJ, Burkard ME, Ahmad N. 2018. Centriole overduplication is the predominant mechanism leading to centrosome amplification in melanoma. Mol Cancer Res. 16(3):517-527. PMID: 29330283

Denu RA, Burkard ME. 2017. Synchronous bilateral breast cancer in a patient with nager syndrome. Clin Breast Cancer. 17(3):e151-e153. PMID: 28139434

Kim H, Johnson JM, Lera RF, Brahma S, Burkard ME. 2017. Anillin phosphorylation controls timely membrane association and successful cytokinesis. PLoS Genet. 13(1):e1006511. PMID: 28081137

Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ. 2017. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (hr+) metastatic breast cancer. Invest New Drugs. 35(1):87-94. PMID: 27826831

Lera RF, Potts GK, Suzuki A, Johnson JM, Salmon ED, Coon JJ, Burkard ME. Decoding Polo-kinase 1 signaling along the kinetochore-centromere axis. Nat Chem Biol 2016. PMID: 27043190

Lasek AL, McPherson BM, Trueman NG, Burkard ME. The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. PLoS One. 2016 Feb 26;11(2):e0150225. doi: 10.1371/journal.pone.0150225. eCollection 2016. PMID: 26919439

Denu RA, Zasadil LM, Kanugh C, Laffin J, Weaver BA, Burkard ME. Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. BMC Cancer. 2016 Jan 29;16(1):47. doi: 10.1186/s12885-016-2083-x. PMID: 26832928

Choudhary A, Zachek B, Lera RF, Zasadil LM, Lasek A, Denu RA, Kim H, Kanugh C, Laffin JJ, Harter JM, Wisinski KB, Saha S, Weaver BA, Burkard ME. Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. Mol Cancer Ther. 2016 Jan;15(1):48-59. doi: 10.1158/1535-7163.MCT-15-0527. Epub 2015 Nov 19. PMID: 26586723

Kim H, Guo F, Brahma S, Xing Y, Burkard ME. Centralspindlin assembly and 2 phosphorylations on MgcRacGAP by Polo-like kinase 1 initiate Ect2 binding in early cytokinesis. Cell Cycle. 2014 Sep 15;13(18):2952-61. doi: 10.4161/15384101.2014.947201. PMID:25486482

Rampurwala MM, Rocque GB, Burkard ME. Update on adjuvant chemotherapy for early breast cancer. Breast Cancer (Auckl). 2014 Oct 8;8:125-33. doi: 10.4137/BCBCR.S9454. eCollection 2014. Review. PMID: 25336961

Robins HI, Burkard ME, Halberg RB. "TRIMing" the patient population to increase the benefit of mTOR inhibition. J Natl Cancer Inst. 2014 Apr 28;106(5). pii: dju095. doi: 10.1093/jnci/dju095.PMID: 2477710

Choudhary A, Lera RF, Martowicz ML, Oxendine K, Laffin JJ, Weaver BA, Burkard ME. Interphase cytofission maintains genomic integrity of human cells after failed cytokinesis. PNAS. 2013 Aug 6;110(32):13026-31. doi: 10.1073/pnas.1308203110. Epub 2013 Jul 22.PMID: 23878225

Lera RF, Burkard ME. High mitotic activity of Polo-like Kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells. J Biol Chem Epub 2012 Oct 27. PMID: 23105120

Lera RF, Burkard ME. The final link: tapping the power of chemical genetics to connect the molecular and biologic functions of mitotic protein kinases. 2012 Oct 17;17(10):12172-86. PMID: 23075814 doi: 10.3390/molecules171012172.

Burkard ME, Santamaria A, Jallepalli PV. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. ACS Chem Biol. 2012 June 15; 7 (6): 978-81. Epub 2012 March 20. PMID: 22422077 PMCID: PMC3376236.

Burkard ME. Integrating the NCI-60 Data with “Omics” for Drug Discovery. Drug Dev Res. 2012 Oct 18; 73 (7):420-9. DOI: 10.1002/ddr.21033.

Tevaarwerk A, Burkard ME, Wisinski KB, Shafer MM, Davis LA, Gogineni J, Crone E, Hansen KE. Aromatase Inhibitors and Calcium Absorption in Early Stage Breast Cancer. Breast Cancer Res Treat. 2012 Feb 8 [Epub ahead of print], PMID: 22350731 PMCID: PMC3376688.

Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME. Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Res Treat. 2012 Jan; 131(2): 713-21. Epub 2011 Nov 8. PMID: 22065290 PMCID: PMC3329126.

Burkard ME, Jallepalli PV. Validating cancer drug targets through chemical genetics. Biochim Biophys Acta 2010 Aug 12, epub (Invited Review). PMID: 20708654

Burkard ME, Maciejowski J, Rodriguez-Bravo V, Repka M, Lowery DM, Clauser KR, Zhang C, Shokat KM, Carr SA, Yaffe MB, Jallpalli PV. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLOS Biology, 7, e1000111, 2009. PMID: 19468302 PMCID: PMC2680336.

Burkard ME, Randall CL, Larochelle S, Zhang C, Shokat KM, Fisher RP, Jallepalli PV. Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci USA 104, 4383-6, 2007. PMID: 17360533 PMCID: PMC1838611.